Analysis of treatment efficacy and prognosis associated with nasopharyngeal carcinoma using EBV-related biomarkers

DOI
  • WAKISAKA Naohiro
    Division of Otolaryngology-Head and Neck Surgery, Kanazawa University
  • HIRAI Nobuyuki
    Division of Otolaryngology-Head and Neck Surgery, Kanazawa University
  • KONDO Satoru
    Division of Otolaryngology-Head and Neck Surgery, Kanazawa University
  • YOSHIZAKI Tomokazu
    Division of Otolaryngology-Head and Neck Surgery, Kanazawa University

Bibliographic Information

Other Title
  • EBV 関連バイオマーカーによる上咽頭癌の治療効果・予後判定

Search this article

Abstract

<p>Epstein-Barr virus (EBV) is involved in carcinogenesis and progression in most cases of nasopharyngeal carcinoma (NPC). Standard treatment in Western countries is concurrent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy (AC). However, the treatment completion rate is only 55%, and a meta-analysis failed to show the advantage of adding AC following CCRT. Now, clinical trials adding AC only to high-risk patients according to high copy numbers of EBV-DNA (BamHI-W fragment) as biomarker are in progress internationally. In recent years, vesicles called exosomes that enclose RNA and/or protein in cells were found to function as intercellular messengers, and they are released into extracellular fluids. Exosomes are released from living cells, and RNAs that are encapsulated in them can be present stably even in blood. Therefore, we examined whether EBV-encoded small RNAs (EBERs) are present in the serum of NPC patients. In addition, we compared this new candidate biomarker and existing markers such as EBV antibody titers and imaging diagnosis, with respect to the response to treatment and prognostic assessment.</p>

Journal

  • jibi to rinsho

    jibi to rinsho 61 (Suppl.1), S66-S71, 2015-11-20

    JIBI TO RINSHO KAI

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top